Drug Profile
mRNA 2752
Alternative Names: iTu triple combination - Moderna Therapeutics; mRNA intratumoral immuno-oncology therapeutics - Moderna Therapeutics; mRNA-2752; OX40L/IL-23/IL-36γLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Moderna Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins; Lipids; Proteins; RNA
- Mechanism of Action IL36G protein expression stimulants; Interleukin 23 expression stimulants; OX40 ligand expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Malignant melanoma
- No development reported Breast cancer; Lymphoma; Solid tumours
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-0 development in Breast-cancer(Combination therapy) in USA (Intralesional, Injection)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Late-stage disease, Second-line therapy or greater) in Israel (Intratumoural, Injection)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Intratumoural, Injection)